Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review
Dylan Evans, Joanne Voisey, Jennifer H Gunter, Fiona Rae · 2026
Read Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review by Dylan Evans, Joanne Voisey, Jennifer H Gunter, Fiona Rae (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13271296.txt.
Description
Dylan Evans is lead author of a 2026 systematic review on whether two changes in the EGFR gene predict response to EGFR-targeted drugs in recurrent glioblastoma, the most aggressive brain tumour type. Extra copies of EGFR and a mutated form called EGFRvIII are common in this cancer, yet their value for choosing treatment was unclear.
Searching three databases for studies from 2010 to 2025, the team kept twelve studies covering 565 patients. Median overall survival ranged from 5.7 to 10.3 months across studies, with no consistent survival benefit tied to either marker. Most studies were single-arm and mixed in design. The authors conclude neither marker should guide treatment choices outside clinical trials.
Catalog record
| CREATOR | Dylan Evans, Joanne Voisey, Jennifer H Gunter, Fiona Rae |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45339 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |